Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Justin M Oldham

Showing results (1-10 of 163) with videos related to

Pageof 17
Sort By:
American Journal of Respiratory and Critical Care Medicine|November 23, 2020
Interstitial Lung Abnormalities and Aging Biomarkers: A MediationJustin M Oldham
The Lancet. Respiratory Medicine|October 4, 2019
Interstitial lung disease: perhaps unclassifiable, but not untreatableJustin M Oldham
Annals of the American Thoracic Society|April 2, 2019
Looking at the Airway to Understand Interstitial Lung DiseaseJustin M Oldham
The Lancet. Respiratory Medicine|January 7, 2021
Treatment of systemic sclerosis-associated interstitial lung disease: a work in progressJustin M Oldham
Ebiomedicine|July 6, 2021
Fibrotic lung disease: A molecular glimpse into severe Covid-19?Paolo Spagnolo, Justin M Oldham
Chest|May 10, 2025
Rebuttal From Drs Oldham and CottinJustin M Oldham, Vincent Cottin
Chest|May 10, 2025
COUNTERPOINT: Should the Progressive Pulmonary Fibrosis Clinical Practice Guideline Be Adopted for Clinical Practice? NoJustin M Oldham, Vincent Cottin
American Journal of Respiratory and Critical Care Medicine|April 21, 2022
On Target: CYFRA 21-1 as an Idiopathic Pulmonary Fibrosis BiomarkerPaolo Spagnolo, Justin M Oldham
Respiratory Medicine|April 22, 2014
Idiopathic pulmonary fibrosis: early detection and referralJustin M Oldham, Imre Noth
Clinics in Chest Medicine|May 24, 2021
Rethinking Idiopathic Pulmonary FibrosisJustin M Oldham, Carlo Vancheri
Pageof 17

Showing results (1-10 of 163) with videos related to

Sort By:
Pageof 17
American Journal of Respiratory and Critical Care Medicine|November 23, 2020
Interstitial Lung Abnormalities and Aging Biomarkers: A MediationJustin M Oldham
The Lancet. Respiratory Medicine|October 4, 2019
Interstitial lung disease: perhaps unclassifiable, but not untreatableJustin M Oldham
Annals of the American Thoracic Society|April 2, 2019
Looking at the Airway to Understand Interstitial Lung DiseaseJustin M Oldham
The Lancet. Respiratory Medicine|January 7, 2021
Treatment of systemic sclerosis-associated interstitial lung disease: a work in progressJustin M Oldham
Ebiomedicine|July 6, 2021
Fibrotic lung disease: A molecular glimpse into severe Covid-19?Paolo Spagnolo, Justin M Oldham
Chest|May 10, 2025
Rebuttal From Drs Oldham and CottinJustin M Oldham, Vincent Cottin
Chest|May 10, 2025
COUNTERPOINT: Should the Progressive Pulmonary Fibrosis Clinical Practice Guideline Be Adopted for Clinical Practice? NoJustin M Oldham, Vincent Cottin
American Journal of Respiratory and Critical Care Medicine|April 21, 2022
On Target: CYFRA 21-1 as an Idiopathic Pulmonary Fibrosis BiomarkerPaolo Spagnolo, Justin M Oldham
Respiratory Medicine|April 22, 2014
Idiopathic pulmonary fibrosis: early detection and referralJustin M Oldham, Imre Noth
Clinics in Chest Medicine|May 24, 2021
Rethinking Idiopathic Pulmonary FibrosisJustin M Oldham, Carlo Vancheri
Pageof 17